Login to Your Account



UP up, and a way to FDA: Cara phase II/III outcome in itch more than hot air

By Randy Osborne
Staff Writer

Tuesday, March 28, 2017

Lack of a dose response across the three levels of drug tested in part A of the phase II/III turned out to be no big deal for Cara Therapeutics Inc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription